特应性皮炎外用治疗试验中临床医生评估的疗效结局测量工具的敏感性:系统综述与meta分析
该系统综述与meta分析比较了2000年至2020年发表的15项外用治疗特应性皮炎(AD)随机对照试验中14种临床医生评估的疗效结局测量工具(OMI)的敏感性。连续型OMI的治疗效应量显著高于二分类OMI(P=0.006);EASI、IGA、BSA和SCORAD的敏感性总体相似,其中BSA的效应量估计较小。连续型OMI可能为小样本概念验证试验提供更高检验效能。
要点
- 连续型OMI的治疗效应量显著高于二分类OMI(P=0.006)。
- EASI、IGA、BSA和SCORAD的敏感性总体相似,BSA效应量估计较小。
- 连续型OMI或可为小样本外用治疗AD的概念验证试验提供更高检验效能。
核心结论
- 在特应性皮炎外用治疗临床试验中,连续型OMI的治疗效应量显著高于二分类OMI(P=0.006)。
- 连续型OMI可能为小样本概念验证试验提供更高检验效能。
研究设计与样本
- 系统综述与meta分析,纳入2000年1月1日至2020年4月7日发表的15项外用治疗AD的对照试验,共3313例受试者,评估14种OMI。
- 计算第4周报告的治疗效应量及其95%置信区间(CI),通过合并标准化均数差(Cohen's d和Cohen's h)比较OMI敏感性。
主要发现
- 连续型OMI的治疗效应量显著高于二分类OMI(P=0.006)。
- EASI、IGA、BSA和SCORAD在可用参数上的敏感性总体相似,BSA的总体效应量估计较小。
关键数值与推荐
- 敏感性比较基于至少3项研究报告的任意两种OMI-参数组合的标准化均数差(Cohen's d和Cohen's h)。
- 评估参数包括第4周活性药物与溶媒的差异、第4周较基线的变化(CFB)和较基线的百分比变化(%CFB)。
临床怎么用
- 在小样本外用治疗AD的概念验证试验中,优先选择连续型OMI可能提高检验效能。
- EASI、IGA、SCORAD敏感性相似,BSA效应量估计较小,选择工具时需结合试验目的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rising prevalence of atopic dermatitis (AD) in developing countries and its substantial socioeconomic impact have furthered research over the last two decades giving way to advances in its aetiopathogenesis and treatment. Topical therapies targeting newly identified AD signalling pathways are being developed. Numerous clinician-assessed disease severity outcome measurement instruments (OMIs) are available to evaluate the efficacy of investigational treatments in proof-of-concept (POC) trials for AD. However, little is known about the comparative sensitivity of these efficacy OMIs. We performed a systematic review and meta-analysis to compare the sensitivity of different OMIs in controlled trials of topical therapies for AD published between January 1, 2000 and April 7, 2020. Treatment effect size of OMIs reported at Week 4 was calculated with 95% Confidence Interval (CI). The sensitivity of OMIs was compared by pooling the standardized difference between means (Cohen's d and Cohen's h) for any two OMI-parameter combinations that were reported in ≥3 studies identified in our systematic review. Assessed parameters were difference between active and vehicle at Week 4 and change from baseline [CFB] and percentage change from baseline [%CFB] at Week 4. We identified a total of 15 studies with 3313 subjects examining 14 different OMIs were included in this quantitative meta-analysis. Continuous OMIs had a significantly higher treatment effect size vs. dichotomous OMIs (P = 0.006). Comparisons of Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), body surface area (BSA) and SCORing Atopic Dermatitis (SCORAD) for available parameters were performed and generally had a similar sensitivity, with BSA showing smaller overall effect size estimates. In conclusion, continuous OMIs used in topical clinical trials for AD had significantly higher treatment effect sizes when compared to dichotomous OMIs. Continuous OMIs could provide more power for POC trials with a small sample size in atopic dermatitis with topical therapies.
引用
- Légaré S, Chagnon M, Palijan A, et al. Sensitivity of clinician-assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021. PMID: 34661930. doi:10.1111/jdv.17743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。